|
|
|
| Clinical efficacy of Zishenyutai pills combined with dydrogesterone for treating women with recurrent spontaneous abortion caused by luteal insufficiency |
| The Second People's Hospital of Luqiao District of Taizhou, Zhejiang Province, 318058 |
|
|
|
|
Abstract Objective: To observe the clinical efficacy of Zishenyutai pills combined with dydrogesterone for treating women with recurrent spontaneous abortion caused by luteal insufficiency. Methods: 150 women with recurrent spontaneous abortion (RSA) caused by luteal insufficiency were included and were randomly divided into the study group and the control group (75 cases in each group) from August 2016 to August 2017. The women in the control group were treated by dydrogesterone orally, and the women in the study group were treated by Zishenyutai pills combined with dydrogesterone. The occurrence of adverse drug reactions of women in the two groups during treatment was recorded, and the changes of serum P, HCG, TNF-a, IL-2, IL-6 and IL-10 levels of women were compared between the two groups before pregnancy and during 8 gestational weeks. The overall curative effect of women after treatment was evaluated, and the successful rate of tocolytic therapy and the incidence of spontaneous abortion again of all included women during this pregnancy were counted. Results: After treatment, the levels of serum P and HCG of all women had increased significantly (P<0.05), and the levels of serum P and HCG of women in the study group were significant higher than those of women in the control group (P<0.05). During 8 gestational weeks, the levels of serum TNF-a and IL-2 of women in both groups had increased significantly after treatment, but the levels of IL-6 and IL-10 had decreased significantly (P<0.05). After women treated to 8 gestational weeks, the levels of serum TNF-a and IL-2 of women in the study group were significant lower than those of women in the control group, while the levels of IL-6 and IL-10 were significant higher (P<0.05). The total effective rate and the successful rate of tocolytic therapy of women in the study group were 90.7% and 85.3%, which were significant higher than those (69.3% and 62.7%) of women in the control group (P<0.05). During the treatment, the incidence of adverse drug reactions of women in the study group was 6.7%, which had no significant different from that (4.0%) of women in the control group (P>0.05). Conclusion: Zishenyutai pills combined with dydrogesterone can significantly increase the levels of serum P and HCG of women with RSA caused by luteal insufficiency, effectively regulate their levels of inflammatory related factors, improve their therapeutic rate, alleviate their related clinical symptoms, and reduce the incidence of next RSA, and it is also have good safety.
|
|
|
|
|
|
|
|
|
